Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer.
Yada KanjanapanDaniel GilbourdGanesalingam PranavanPublished in: BMJ case reports (2020)
Cisplatin is a widely used chemotherapeutic agent for many cancer types. Its toxicity profile includes drug-induced vascular damage. Clinicians should be aware of its varied presentation, including acute and chronic vascular events involving the arterial and venous system. This is a case of an otherwise well 32-year-old man with testicular cancer who received bleomycin/etoposide/cisplatin, and presented following two cycles of chemotherapy with homonymous hemianopia secondary to acute stroke. Acute arterial complications are rare, but clinicians should maintain a high index of suspicion for such events, even in a patient who otherwise has no vascular risk factors. Primary and secondary prevention measures including lifestyle modifications (smoking cessation, diet and exercise), blood pressure and cholesterol management, and antiplatelet therapy should be considered in patients exposed to cisplatin, during and following their treatment.
Keyphrases
- drug induced
- liver injury
- papillary thyroid
- liver failure
- smoking cessation
- risk factors
- antiplatelet therapy
- blood pressure
- squamous cell
- respiratory failure
- physical activity
- oxidative stress
- end stage renal disease
- acute coronary syndrome
- chronic kidney disease
- palliative care
- cardiovascular disease
- replacement therapy
- type diabetes
- newly diagnosed
- ejection fraction
- aortic dissection
- high intensity
- coronary artery disease
- atrial fibrillation
- body composition
- low density lipoprotein
- rectal cancer
- chemotherapy induced
- patient reported